PDCD1 and nonpapillary renal cell carcinoma: To further investigate the prognostic value of FCER1G, we downloaded the bulk RNA-seq and clinical data of the CheckMate 025 clinical trial, based on which Nivolumab (anti-PD-1) was approved by the Food and Drug Administration for the treatment of ccRCC [20].